India Launches Precision Medicine Drive: Genomics, AI & Bio‑E3 Policy Propel Healthcare Revolution
Union Minister <strong>Dr. Jitendra Singh</strong) announced that India is entering a new era of personalised and precision medicine powered by genomics, AI and biotechnology. Initiatives such as the <span class="key-term" data-definition="Genome India initiative — Government programme to sequence Indian genomes for health research (GS3: Science & Technology)">Genome India</span> project, the <span class="key-term" data-definition="Bio‑E3 Policy — India’s Biotechnology for Economy, Employment and Environment policy to boost biomanufacturing (GS3: Science & Technology)">Bio‑E3 Policy</span>, and the <span class="key-term" data-definition="SHANTI Act — legislation allowing private participation in India’s nuclear sector, promoting SMR and nuclear medicine (GS3: Science & Technology)">SHANTI Act</span> aim to make India a global leader in biotech, improve early disease detection and position the country as a cost‑effective healthcare hub.
Overview of India’s Precision Medicine Drive Union Minister of State (Independent Charge) for Science & Technology, Dr. Jitendra Singh , addressed the NXT Summit 2026, declaring that India is moving into a transformative era of personalised and precision medicine . The thrust is powered by genomics , AI and advanced biotechnology. Key Developments India’s vast genetic diversity (4,000‑5,000 distinct communities) provides a unique platform for large‑scale genomic research. The Genome India project has sequenced 10,000 genomes; the target is one million to strengthen preventive healthcare. Launch of the Bio‑E3 Policy to accelerate biomanufacturing, positioning India among the top global players. Successful gene‑therapy trials for haemophilia and development of DNA‑based COVID‑19 vaccine and indigenous HPV vaccine. AI‑enabled early‑detection programmes, especially for breast cancer, using thermal imaging in mobile health units. Collaboration between the Department of Space and AIIMS on space‑medicine research. Introduction of the SHANTI Act to invite private investment in nuclear technologies and medicine. Creation of a ₹1 lakh crore RDI Fund for biotech, nuclear science and emerging healthcare solutions. Important Facts India now ranks third in the Asia‑Pacific region for bio‑manufacturing, supported by bio‑foundries, clusters and Bio‑NEST incubators. The government’s push has made India a cost‑effective, high‑quality healthcare destination, attracting global collaborations through platforms like the Parliamentarians’ Forum on Life Sciences. UPSC Relevance These developments intersect with several GS papers: GS3 – Science & Technology (genomics, AI, biotechnology, nuclear energy), GS1 – Indian Heritage & Culture (India’s genetic diversity), and GS4 – Ethics (ethical aspects of gene therapy and AI in healthcare). Understanding the policy framework (Bio‑E3, SHANTI Act, RDI Fund) is essential for questions on health sector reforms, innovation ecosystems and India’s global positioning. Way Forward Scale up genome sequencing to the million‑genome target, ensuring robust data privacy and ethical oversight. Strengthen public‑private partnerships under the RDI Fund to commercialise biotech breakthroughs. Expand AI‑driven diagnostic networks to remote areas, integrating them with existing primary health centres. Monitor gene‑therapy outcomes and establish regulatory guidelines to address safety and accessibility. Leverage space‑medicine research for innovations in tele‑health and remote monitoring. Collectively, these steps aim to cement India’s leadership in the next industrial revolution driven by biotechnology and precision healthcare.
Quick Reference
Key Insight
India's Precision Medicine Drive positions biotech as a strategic health and economic priority
Key Facts
- Genome India has sequenced 10,000 genomes; target is 1 million by 2028 to enable preventive healthcare.
- India’s genetic diversity spans 4,000‑5,000 distinct communities, offering a unique research base.
- Bio‑E3 Policy and a ₹1 lakh crore RDI Fund aim to make India a top‑3 bio‑manufacturing hub in Asia‑Pacific.
- SHANTI Act (2026) permits private participation in nuclear medicine and small modular reactors.
- AI‑enabled mobile units are piloting thermal‑imaging breast‑cancer screening in remote districts.
Background
The drive aligns with GS‑3 themes of emerging technologies, health sector reforms and innovation ecosystems, while also touching GS‑1 (India's genetic heritage) and GS‑4 (ethical, privacy and regulatory aspects of genomics and AI). It reflects a shift from curative to preventive, data‑driven healthcare, leveraging public‑private partnerships and strategic policy instruments.
UPSC Syllabus
- Essay — Science, Technology and Society
- Prelims_GS — Biology and Health
- GS3 — Developments in science and technology and their applications
- GS3 — IT, Space, Computers, Robotics, Nano-technology, Bio-technology and IPR
- GS2 — Government policies and interventions for development
- GS2 — Functions and responsibilities of Union and States
- Essay — Economy, Development and Inequality
- Essay — Youth, Health and Welfare
- Prelims_GS — Science and Technology Applications
- GS1 — Poverty and Developmental Issues
Mains Angle
In a Mains answer, discuss how the Precision Medicine Drive integrates science‑technology policy (Bio‑E3, SHANTI Act, RDI Fund) with health governance, and evaluate its implications for equity, ethics and India's global standing. (GS‑3)